{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:38:21Z","timestamp":1777693101415,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T00:00:00Z","timestamp":1519084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["#17H04211"],"award-info":[{"award-number":["#17H04211"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s12185-018-2421-7","type":"journal-article","created":{"date-parts":[[2018,2,20]],"date-time":"2018-02-20T05:47:12Z","timestamp":1519105632000},"page":"673-680","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Mutational subtypes of JAK2 and CALR correlate with different clinical features in Japanese patients with myeloproliferative neoplasms"],"prefix":"10.1007","volume":"107","author":[{"given":"Kyohei","family":"Misawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marito","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Ochiai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soji","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Shirane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Edahiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Gotoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akimichi","family":"Ohsaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-9126","authenticated-orcid":false,"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,20]]},"reference":[{"issue":"6","key":"2421_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s12185-017-2246-9","volume":"105","author":"M Imai","year":"2017","unstructured":"Imai M, Araki M, Komatsu N. Somatic mutations of calreticulin in myeloproliferative neoplasms. Int J Hematol. 2017;105(6):743\u20137.","journal-title":"Int J Hematol"},{"issue":"25","key":"2421_CR2","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","volume":"369","author":"T Klampfl","year":"2013","unstructured":"Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379\u201390.","journal-title":"N Engl J Med"},{"issue":"25","key":"2421_CR3","first-page":"2379","volume":"124","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Pascutto C, Guglielmelli P, Mart\u00ednez-Trillos A, Casetti IC, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014;124(25):2379\u201390.","journal-title":"Blood"},{"issue":"10","key":"2421_CR4","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","volume":"123","author":"E Rumi","year":"2014","unstructured":"Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544\u201351.","journal-title":"Blood"},{"issue":"12","key":"2421_CR5","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.leukres.2011.06.016","volume":"35","author":"S Morishita","year":"2011","unstructured":"Morishita S, Komatsu N, Kirito K, Koda AH, Sekiguchi Y, Tsuneda S, et al. Alternately binding probe competitive PCR as a simple, cost-effective, and accurate quantification method for JAK2V617F allele burden in myeloproliferative neoplasms. Leuk Res. 2011;35(12):1632\u20136.","journal-title":"Leuk Res"},{"issue":"9","key":"2421_CR6","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00277-008-0512-x","volume":"87","author":"I Rapado","year":"2008","unstructured":"Rapado I, Albizua E, Ayala R, Hern\u00e1ndez JA, Garcia-Alonso L, Grande S, et al. Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases. Ann Hematol. 2008;87(9):741\u20139.","journal-title":"Ann Hematol"},{"issue":"8","key":"2421_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0104958","volume":"9","author":"H Takei","year":"2014","unstructured":"Takei H, Morishita S, Araki M, Edahiro Y, Sunami Y, Hironaka Y, et al. Detection of MPLW515L\/K mutations and determination of allele frequencies with a single-tube PCR assay. PLoS One. 2014;9(8):1\u20138.","journal-title":"PLoS One"},{"issue":"2","key":"2421_CR8","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.3324\/haematol.2014.115113","volume":"100","author":"S Shirane","year":"2015","unstructured":"Shirane S, Araki M, Morishita S, Edahiro Y, Takei H, Yoo Y, et al. JAK2, CALR, and MPL mutation spectrum in japanese patients with myeloproliferative neoplasms. Haematologica. 2015;100(2):e46\u20138.","journal-title":"Haematologica"},{"issue":"2","key":"2421_CR9","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1038\/leu.2015.277","volume":"30","author":"D Pietra","year":"2016","unstructured":"Pietra D, Rumi E, Ferretti VV, Di Buduo CA, Milanesi C, Cavalloni C, et al. Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia. 2016;30(2):431\u20138.","journal-title":"Leukemia"},{"issue":"20","key":"2421_CR10","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Borowitz MJ, Le Beau MM, Bloomfield CD, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391\u2013405.","journal-title":"Blood"},{"key":"2421_CR11","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s12185-014-1567-1","volume":"99","author":"Y Edahiro","year":"2014","unstructured":"Edahiro Y, Morishita S, Takahashi K, Hironaka Y, Yahata Y, Sunami Y. JAK2 V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan. Int J Hematol. 2014;99:625\u201334.","journal-title":"Int J Hematol"},{"issue":"48","key":"2421_CR12","first-page":"452","volume":"2013","author":"Y Kanda","year":"2012","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant. 2012;2013(48):452\u20138.","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2421_CR13","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874\u201381.","journal-title":"Leukemia"},{"issue":"60","key":"2421_CR14","doi-asserted-by":"publisher","first-page":"101735","DOI":"10.18632\/oncotarget.21594","volume":"8","author":"E Rumi","year":"2017","unstructured":"Rumi E, Boveri E, Bellini M, Pietra D, Ferretti VV, Antonio ES, et al. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget. 2017;8(60):101735\u201344.","journal-title":"Oncotarget"},{"key":"2421_CR15","doi-asserted-by":"publisher","first-page":"e360","DOI":"10.1038\/bcj.2015.90","volume":"5","author":"P Guglielmelli","year":"2015","unstructured":"Guglielmelli P, Rotunno G, Fanelli T, Pacilli A, Brogi G, Calabresi L, et al. Validation of the differential prognostic impact of type 1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis. Blood Cancer J. 2015;5:e360.","journal-title":"Blood Cancer J."},{"issue":"5","key":"2421_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1056\/NEJMoa065202","volume":"356","author":"LM Scott","year":"2007","unstructured":"Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. Exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356(5):459\u201368.","journal-title":"N Engl J Med."},{"issue":"10","key":"2421_CR17","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","volume":"117","author":"F Passamonti","year":"2011","unstructured":"Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117(10):2813\u20136.","journal-title":"Blood"},{"issue":"4","key":"2421_CR18","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/leu.2016.351","volume":"31","author":"F Passamonti","year":"2017","unstructured":"Passamonti F, Mora B, Giorgino T, Guglielmelli P, Cazzola M, Maffioli M, et al. Driver mutations\u2019 effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia. 2017;31(4):970.","journal-title":"Leukemia"},{"issue":"1","key":"2421_CR19","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/leu.2014.270","volume":"29","author":"X Cabagnols","year":"2015","unstructured":"Cabagnols X, Defour JP, Ugo V, Ianotto JC, Mossuz P, Mondet J, et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocythemia: relevance for disease evolution. Leukemia. 2015;29(1):249\u201352.","journal-title":"Leukemia"},{"issue":"10","key":"2421_CR20","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1182\/blood-2015-11-679571","volume":"127","author":"C Marty","year":"2016","unstructured":"Marty C, Pecquet C, Nivarthi H, El-Khoury M, Chachoua I, Tulliez M, et al. Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis. Blood. 2016;127(10):1317\u201324.","journal-title":"Blood"},{"issue":"8","key":"2421_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/ajh.23743","volume":"89","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014;89(8):121\u20134.","journal-title":"Am J Hematol"},{"issue":"10","key":"2421_CR22","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1016\/j.exphem.2009.07.005","volume":"37","author":"K Hussein","year":"2009","unstructured":"Hussein K, Bock O, Theophile K, von Neuhoff N, Buhr T, Schlu\u00e9 J, et al. JAK2 V617F allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol. 2009;37(10):1186\u201393.","journal-title":"Exp Hematol"},{"issue":"7","key":"2421_CR23","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22(7):1299\u2013307.","journal-title":"Leukemia"},{"issue":"2","key":"2421_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s12185-014-1721-9","volume":"101","author":"S Shirane","year":"2015","unstructured":"Shirane S, Araki M, Morishita S, Edahiro Y, Sunami Y, Hironaka Y, et al. Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia. Int J Hematol. 2015;101(2):148\u201353.","journal-title":"Int J Hematol"},{"issue":"23","key":"2421_CR25","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1200\/JCO.2010.34.5298","volume":"29","author":"T Barbui","year":"2011","unstructured":"Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Ruggeri M, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29(23):3179\u201384.","journal-title":"J Clin Oncol"},{"issue":"5","key":"2421_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1038\/leu.2015.360","volume":"30","author":"H Gisslinger","year":"2016","unstructured":"Gisslinger H, Jeryczynski G, Gisslinger B, W\u00f6lfler A, Burgstaller S, Buxhofer-Ausch V, et al. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia. 2016;30(5):1126\u201332.","journal-title":"Leukemia"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-018-2421-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-018-2421-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T09:56:39Z","timestamp":1589450199000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-018-2421-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,20]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1007\/s12185-018-2421-7","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,20]]},"assertion":[{"value":"1 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This study was carried out as a research program of the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct), The Japan Agency for Medical Research and Development, and Ministry of Education, Culture, Sports, Science and Technology of Japan. Part of this work was supported by Japan Society for the Promotion of Science KAKENHI Grant #17H04211. The authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}